60 Degrees Pharmaceuticals Reports Clinical Improvement in All Five Completed Babesiosis Study Patients
Bitget2026/10/27 12:12- 60 Degrees Pharmaceuticals announced results showing clinical improvement in all five patients completing tafenoquine combination treatment for relapsing babesiosis.
- All five tested negative on conventional parasite tests; more sensitive testing detected residual infection in one patient.
- The company plans to pursue accelerated approval if its efficacy submission relies primarily on immunosuppressed patients with relapsing babesiosis.
- A separate randomized hospital trial is scheduled for unblinding in January 2027, with FDA regulatory discussions planned afterward.
- Tafenoquine is approved for malaria prevention in the United States, but not for babesiosis treatment or prevention.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Vodafone (VOD.US) Swings to Loss in First Half, German Operations Major Drag
Vodafone (VOD.US) released its financial results for the first half of fiscal year 2027.
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Crypto prices
More
